Innate Pharma

Innate Pharma is a global, clinical-stage oncology-focused biotech company founded in 1999 and headquartered in France. The company is dedicated to improving treatment and clinical outcomes for cancer patients through therapeutic antibodies that harness the immune system to fight cancer. Innate Pharma's broad pipeline of antibodies includes several potentially first-in-class clinical and preclinical candidates in cancers with high unmet medical need.

Innate Pharma has been a pioneer in the understanding of natural killer cell (NK cell) biology and has expanded its expertise in the tumor microenvironment and tumor-antigens, as well as antibody engineering. The innovative approach has resulted in a diversified proprietary portfolio and major alliances with leaders in the biopharmaceutical industry, including Bristol-Myers Squibb, Novo Nordisk A/S, Sanofi, and a multi-products collaboration with AstraZeneca.

The company, listed on Euronext Paris and Nasdaq in the US, recently received a $75.00M post-IPO secondary investment on 02 May 2022. Innate Pharma's strong focus on oncology and its strategic collaborations position it as an innovative player in the biopharma, biotechnology, and pharmaceutical industries, with potential for continued growth and impact in the field of cancer treatment.